Dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson׳s disease

This data article presents a dataset of total, oligomeric alpha-synuclein and hemoglobin levels in plasma of drug-naïve PD patients and controls. This is the first attempt to assess the effect of hemolysis rate on oligomeric alpha-synuclein levels in peripheral plasma. The data are associated with the research article “Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson׳s disease” (Pchelina et al., 2016) [1].


a b s t r a c t
This data article presents a dataset of total, oligomeric alphasynuclein and hemoglobin levels in plasma of drug-naïve PD patients and controls. This is the first attempt to assess the effect of hemolysis rate on oligomeric alpha-synuclein levels in peripheral plasma. The data are associated with the research article "Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease" (Pchelina et  Blood plasma samples were collected using centrifugation

Experimental features
The relationship between total, oligomeric alpha-synuclein and hemoglobin levels in plasma in Parkinson's disease was determined. Data source location St.Petersburg, Russian Federation Data accessibility Data is within this article

Value of the data
These data provide the correlation between oligomeric alpha-synuclein and hemoglobin plasma levels in drug-naive PD patients and controls.
The data are of value for further experiments on the assessing of alpha-synuclein levels in peripheral blood and cerebrospinal fluid (CSF) samples.
The data have significance due to the fact that hemolysis has effect on total but not oligomeric alpha-synuclein levels in peripheral blood plasma.

Sample preparation
Blood plasma samples were collected from 17 drug-naïve patients with iPD (mean age 62.44 79.67, 6 males) and age/sex-matched 18 controls (mean age 63.83 710.86, 10 males). PD patients were diagnosed with PD at Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia. Subjects without neurological disorders were included in the control group. The study was approved by the local ethics committee. All the participating subjects provided informed consent. Samples were collected using centrifugation at 3000 rpm at 4°C for 20 min. All samples were aliquoted and maintained at À 70°C.

ELISA assays to measure total, oligomeric alpha-synuclein and hemoglobin levels
Total alpha-synuclein, oligomeric alpha-synuclein and hemoglobin levels were estimated by means of enzyme-linked immunosorbent assay (ELISA) (Human alpha-synuclein ELISA kit (Invitrogen, USA), Human Synuclein OLIGO kit (ajRoboscreen, Germany) and Hemoglobin (Human) ELISA kit (Abnova, USA), accordingly), as described previously [2][3][4]. Levels of oligomeric alpha-synuclein were estimated by means of ELISA with 5G4 antibodies designated for detection of alpha-synuclein oligomers in human fluid samples [5]. Undiluted plasma samples were examined in case of alphasynuclein measurements. For hemoglobin level estimation plasma samples were diluted according the manufacturer's recommendations. In all ELISA assays each sample was measured in triplicate.

Statistical analysis
To assess differences between groups, the Mann-Whitney test was used, and the correlations were evaluated by exponential regression analysis. The correlations were evaluated using the Spearman correlation coefficient. Sex variables were analyzed by Chi-square and Fisher's exact tests. Experimental data are given as median (min-max). The level of significance was set at p o0.05. Statistical analysis was carried out using SPSS 12.0.

Acknowledgment
We wish to thank the Russian Foundation for Basic Research (research Project no. 16-54-76009) and the ERA.Net RUS Plus Group of Funding Parties (ID230) for financial support.

Transparency document. Supplementary material
Transparency data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2016.11.089.